Windtree Therapeutics received a deficiency letter from Nasdaq stating that its common stock has been below the minimum bid price required for continued listing, but it has been given time to regain compliance.
AI Assistant
WINDTREE THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.